Loading...
Loading...
ADMP| Name | Value |
|---|---|
| Revenues | 1,453.0K |
| Cost of Revenue | 1,788.1K |
| Gross Profit | -335.1K |
| Operating Expense | 6,092.6K |
| Operating I/L | -6,427.7K |
| Other Income/Expense | -2,586.9K |
| Interest Income | 0.0K |
| Pretax | -9,014.6K |
| Income Tax Expense | -9,086.3K |
| Net Income/Loss | 71.7K |
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company that develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. The company's product candidates include SYMJEPI epinephrine pre-filled syringe injectable products for acute allergic reactions, dry powder inhaler products for asthma treatment, and naloxone injection for opioid overdose. Additionally, they offer APC400, a tempol gel for reducing radiation dermatitis, and APC410 for respiratory diseases. Adamis also provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, and veterinary pharmaceutical products for animals.
